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Abstract
Background: In vivo imaging using Annexin A5-based radioligands is a powerful technique for visualizing massive cell
death, but has been less successful in monitoring the modest cell death typically seen in solid tumors after chemotherapy.
Here we combined dynamic positron emission tomography (PET) imaging using Annexin A5 with a serum-based apoptosis
marker, for improved sensitivity and specificity in assessment of chemotherapy-induced cell death in a solid tumor model.
Methodology/Principal Findings: Modest cell death was induced by doxorubicin in a mouse xenograft model with human
FaDu head and neck cancer cells. PET imaging was based on 11C-labeled Sel-tagged Annexin A5 ([11C]-AnxA5-ST) and a size-
matched control. 2-deoxy-2-[18F]fluoro-D-glucose ([18F]-FDG) was utilized as a tracer of tissue metabolism. Serum
biomarkers for cell death were ccK18 and K18 (M30 ApoptosenseH and M65). Apoptosis in tissue sections was verified ex
vivo for validation. Both PET imaging using [11C]-AnxA5-ST and serum ccK18/K18 levels revealed treatment-induced cell
death, with ccK18 displaying the highest detection sensitivity. [18F]-FDG uptake was not affected by this treatment in this
tumor model. [11C]-AnxA5-ST gave robust imaging readouts at one hour and its short half-life made it possible to perform
paired scans in the same animal in one imaging session.
Conclusions/Significance: The combined use of dynamic PET with [11C]-AnxA5-ST, showing specific increases in tumor
binding potential upon therapy, with ccK18/K18 serum measurements, as highly sensitive markers for cell death, enabled
effective assessment of modest therapy-induced cell death in this mouse xenograft model of solid human tumors.
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Introduction
Therapy must be individually optimized if outcomes for cancer
patients are to be improved [1]. Insufficient induction of cell death
in tumors leads to therapeutic failure, while cell death in healthy
tissue is the most common dose-limiting side effect. Analyzing the
timing, tissue localization and extent of cell death induced by
anticancer drugs is therefore necessary for detailed assessments of
both therapeutic efficacy and toxic side effects and this could
dramatically improve clinical care [2,3]. Using similar methods for
evaluating drug effects in animal models, e.g. mice with xenograft
tumors, could reduce the number of animals used to obtain
reliable results, improve efficacy read-outs, shorten the time
required for translation to the clinic and thereby reduce the costs
for drug development. Here we investigated whether positron
emission tomography (PET) imaging of cell death in combination
with analyses of serum markers could provide a strategy for
assessing cell death which is more effective than using either of
these techniques alone.
The most widely used cell death imaging methods available to
date are based on Annexin A5 (AnxA5), a 36 kDa protein which
binds with high affinity to phosphatidylserine (PS) externalized by
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dying (apoptotic) or dead (late apoptotic or necrotic) cells [2,3,4].
99mTc-HYNIC-AnxA5 is currently in Phase II/III trials [5].
However, AnxA5-based imaging techniques can have difficulty
detecting modest responses to therapy such as those often seen
clinically in solid tumors. One reason may be that non-specific
uptake of protein tracers due to enhanced permeability and
retention (EPR), caused by leaky vessels and poor lymphatic
drainage in tumors, may mask small variations in specific uptake
due to cell death [6,7]. We have recently developed a new Sel-tag
[8,9], which was used here for 11C-labeling of AnxA5. To estimate
non-specific tracer uptake due to EPR effects, we also 11C-labeled
a control ligand, size-matched with AnxA5 but designed to lack
probable biological activity in a mammalian host and also shown
here not to bind apoptotic cells. We subsequently evaluated the use
of these two ligands for PET imaging in a xenograft tumor model,
without or with chemotherapy that induces modest cell death. We
also compared the results with those of [18F]-2-fluoro-2-deox-
yglucose ([18F]-FDG), a non-metabolized glucose analogue whose
uptake is largely proportional to the rate of glucose metabolism
[10]. [18F]-FDG is currently the PET ligand most widely used in
the clinical management of many cancer types, including in the
evaluation of therapeutic responses [11].
Monitoring the levels of particular macromolecules released
from tumor cells into serum during therapy [12] can, with its ease
and low cost, provide an attractive complement to imaging. The
cytokeratins, which we monitor here, are useful as circulating
biomarkers of epithelial cell death, due to their limited patterns of
expression and particularly to the fact that they are not expressed
in hematopoietic cells. The release of caspase-cleaved and total
keratin 18 (ccK18 and K18, respectively) to serum has been well
documented in clinical studies after treatment of breast and
prostate cancer patients with cytotoxic drugs [13,14,15]. Toxicity
to off-target organs, particularly the liver [16], can also give
circulating K18 fragments and the extent of these contributions to
the serum levels can not be estimated in humans. However, since
the antibodies in the M30 Apoptosense and M65 ELISA kits used
here are species (human)-specific, serum levels due to effects on
human xenografts in rodents will not be affected by cell death in
off-target tissues because the murine proteins will not be detected
[17].
To be diagnostically useful, methods for assessing cell death
must be sufficiently sensitive to detect the levels of responses that
occur in clinical situations, i.e. not just the relatively rare instances
of complete therapeutic responses with massive apoptosis, which
have been more easy to detect by imaging methods [18,19], but
also the partial responses more commonly encountered with solid
tumors. Therefore, in order to compare the sensitivities of the PET
imaging and serum biomarker methods for assessments of modest
tumor cell death and probe their combined usage, we here utilized
a squamous carcinoma model that is only moderately sensitive to
the drug tested, doxorubicin [20]. We found that the serum
biomarker ccK18 proved to be a highly sensitive tool for
estimating the extent (but not the localization) of total apoptosis
in this model. Dynamic PET imaging for determining the binding
potentials of 11C-labeled Sel-tagged Annexin A5 ([11C]-AnxA5-
ST) provided solid information on the cell death in the tumors
themselves at discrete time points, particularly when non-specific
tumor uptake was estimated using a size-matched control ligand.
Therefore we propose that the combined use of serum biomarkers
for apoptosis together with dynamic PET imaging using [11C]-
AnxA5-ST, preferably compared with a size-matched control
ligand provides a sensitive technique for detecting, localizing and
assessing the extent of cell death induced by chemotherapeutics
even in this modestly responsive xenograft model of human solid
tumors.
Materials and Methods
Materials
If not otherwise specified, all chemicals were obtained from
Sigma-Aldrich Chemical Corporation. Specific materials for
expression of Sel-tagged proteins were previously described
[8,9,21]. The cDNA of human Annexin A5 was purchased from
OriGene Technologies, Inc. whereas cDNA for GFP was obtained
from the pGFPuv plasmid (Clontech).
Expression and purification of Sel-tagged proteins
A nucleotide sequence encoding a bacterial-type SECIS
element and the Sel-tag having the amino acid sequence -Gly-
Cys-Sec-Gly was introduced into the Annexin A5 gene by PCR as
described [8]. The PCR product was cloned into the NdeI-BamHI
sites of pET-15b (Novagen) and the construct was subsequently
transformed into BL21(DE3) E. coli strain (Novagen), with the N-
terminal His-tag from the vector preserved in the construct for
final purification. Protein integrity was also checked by His-tag
western blot using SuperSignal West HisProbe Kit (Thermo). The
size-matched control protein for assessment of EPR effects was
designed to encompass the globular and stable E. coli thioredoxin
scaffold, made redox inactive by mutating its two active site Cys
residues to Ser (mTrx), fused with green fluorescent protein (GFP),
which was Sel-tagged (ST) at its C-terminus yielding mTrx-GFP-
ST. The resulting DNA sequences of both expression plasmids
were verified by DNA sequencing (GATC biotech). The encoded
amino acid sequences of the two ligands with their major
functional determinants indicated are given in Material S1. To
increase the yield of Sec insertion into the Sel-tag, the assistant
plasmid pSUABC was co-transformed into the expression host
bacteria [22] as also previously described in further detail [8].
Upon protein purification based on the N-terminal His-tag of each
protein, we included a thorough wash of the nickel column using
50 column volumes of 0.1% triton X-114 before finally eluting the
proteins with imidazole, which efficiently removes endotoxins
from protein samples [23]. The endotoxin level of different protein
samples was subsequently analyzed by the Karolinska Pharmacy
and found to be below limits of detection (,2.5 endotoxin units/
ml). The purified recombinant proteins were apparently homog-
enous on Coomassie-stained SDS-PAGE analyses and were
obtained at yields of 10–20 mg per liter original bacterial culture,
as mixtures of UGA-truncated and Sec-containing full-length
proteins, as described [8], with an estimated 20–30% Sec content.
They were stored in phosphate-buffered saline at 220uC until use.
Fluorescence labeling
The AnxA5-ST or mTrx-GFP-ST (5 mg/ml in 100 mL PBS;
phosphate buffered saline, 155 mM NaCl, 4 mM phosphate,
pH 7.4) were, upon reduction with 2 mM DTT, incubated for
20 min at 20uC with 5 mM 5-iodoacetamidofluorescein (5-IAF,
dissolved in DMSO, Invitrogen) for derivatization of the Sec
residue in the Sel-tag. The fluorescently labeled proteins, named
[AF]-AnxA5-ST and [AF]-mTrx-GFP-ST, were desalted over
NAP-5 columns (GE Healthcare) and further purified on an
A¨KTAExplorer 10 HPLC system using a Superdex 200 10/300
GL gel filtration column with PBS pH 7.4 as mobile phase. Purity
and fluorescence of the proteins were confirmed by SDS-PAGE
with UV irradiation and Coomassie staining as described [8,9,21].
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Cell culturing
FaDu (human squamous carcinoma) cells (obtained from
ATCC, catalogue nr HTB-43) were cultured in Dulbecco’s
Modified Eagle Medium (D-MEM) with high glucose (Invitrogen)
supplemented with 0.1 mM non-essential amino acids, 10% fetal
bovine serum (FBS), 1 mM sodium pyruvate, 100 units penicillin/
ml, 100 mg streptomycin/ml and 2 mM HEPES at 37uC and 5%
CO2 in a humidified environment. The integrity of the FaDu cell
line was verified with STR profiling cell authentication analysis
(LGC Standards).
Detection of binding to apoptotic cells in culture
FaDu cells were seeded at a density of 100 000 cells/well in 24-
well plates 24 h prior to treatment with different concentrations of
doxorubicin (0.2 mM, 0.5 mM or 2 mM) for 6, 16, 24 and 48 hours.
Upon doxorubicin exposure, cells were washed with PBS and
AnxA5 binding buffer (taken from the FITC AnxA5 apoptosis
detection kit 556547, BD Pharmingen) before incubation with
either 0.5 mg/ml [AF]-AnxA5-ST or [AF]-mTrx-GFP-ST (resus-
pended in AnxA5 binding buffer) for 20 min at 37uC. Finally the
cells were washed with 16PBS and incubated 5 min with 0.5 mg/
ml propidium iodide solution (BD Pharmingen), whereupon
pictures were taken using fluorescence microscopy using a Zeiss
AxioVert 40CFL microscope.
Radiolabeling with 11C
Radiolabeling of the Sel-tagged proteins was performed in
general by the previously published protocol [8]. An aliquot (50 ml)
of [11C]methyl iodide, prepared according to [24], in DMSO
(0.2 ml) was added to the Sel-tagged protein (450 ml, 5 mg/ml)
which had been pre-reduced with 2 mM DTT for $20 min at
room temperature. After reacting for 20 min at 36uC, the product
was eluted from a NAP-5 column pre-equilibrated with divalent
cation-free PBS. Aliquots of the eluted protein were diluted with
saline for immediate injections in the animals. The radiochemical
purity was$% (Superdex 75 10/300 GL gel filtration column (GE
Healthcare) eluted with PBS) and the specific radioactivity 5–
10 GBq/mmol protein.
Ethics statement
This study was performed in strict accordance with the
recommendations regarding animal use at Karolinska Institutet
and in Sweden. The experiments were approved by the
Committee on the Ethics of Animal Experiments of the Northern
Stockholm Area (Stockholms Norra Djurfo¨rso¨ksetiska Na¨mnd) and
covered in full by the permits with numbers N241/07, N323/
09, N85/11, N251/09 and N265/11. Every effort was made to
minimize animal suffering and the specific routines of animal
handling for the current study is described in the text on
methodologies for imaging.
In vivo PET imaging of xenograft tumors
Animals (SCID mice) were housed under sterile laboratory
conditions with food and water ad libitum. FaDu cells (16106 cells
in 0.1 ml PBS) were inoculated subcutaneously into the right flank
of each mouse. The mice, bearing tumors of 5 to 9 mm in
diameter, were used 1–2 weeks after inoculation. In vivo PET
studies were performed using a MicroPET Focus 120 (CTI
Concorde Microsystems) in general as previously described [25].
The mice were either untreated when scanned or were first
injected s.c. with doxorubicin (5 mg/kg) and allowed to recover
until the day of the PET imaging. The PET tracer, [11C]-AnxA5-
ST or [11C]-mTrx-GFP-ST (5–9 MBq in 0.2 ml saline), was
intravenously injected and PET data were collected for 1 h. At
least 30 min after the end of the first scan (allowing decay of low
levels of residual 11C), either the other 11C-labeled protein or
[18F]-FDG (8–10 MBq, obtained from batches made for clinical
PET) was subsequently injected and mice were scanned for an
additional 1 h. At the time point for this second injection, the
originally injected 11C-tracer had decayed to <6% of the original
injected dose, of which only about 4–6% accumulated per gram of
tumor tissue (0.003%). By the last frames of a subsequent [18F]-
FDG scan, this amount would have decreased through decay to
0.00075% id/g, a level that we concluded, if detectable, was an
insignificant contribution to the robust signals from retained [18F]-
FDG. Immediately after the end of all final scans, the mice were
euthanized whereupon tissue and plasma samples were collected
for IHC and ccK18 analyses, respectively.
Data were processed using MicroPET Manager and evaluated
using the Inveon Resarch Workplace (Siemens Medical Solutions)
software. To determine the temporal changes of tracer concen-
trations, regions of interest (ROIs) were drawn on the images by
employing a 75% threshold of the maximum intensity voxels with
consistency to post-mortem measurements of the tumor dimen-
sions. Isocontour-delineations employing a standard threshold cut-
off are standard techniques for minimizing user bias. Control
against the actual size of excised tumor helped ensure that the
generated ROIs were representative of the actual tumor volume.
Radioactivity concentrations (Bq per milliliter) were calculated
automatically by calibrating against a phantom with a known
concentration of radioactivity. Assuming a tissue density of 1 g/
ml, the radioactivity concentrations were divided by the admin-
istered activity to obtain a ROI-derived percent injected dose per
gram of tissue (%ID/g). In comparisons between different
individuals, normalization to the same body weight was per-
formed.
Data were further analyzed by the graphical method developed
by Logan et al. (see [26] and references therein) in combination
with the ‘‘Simplified Reference Tissue Model’’ [27]. Here a
reference region on, in our case, the quadriceps was also drawn
and radioactivity concentrations calculated as above. When fitting
a function of the ROI to a function of the reference region, the
resulting slope of the curve gives the distribution volume ratio
(DVR). By subtracting 1 from the DVR, the binding potential is
generated [26], a quantity that is a direct indication of the specific
binding sites in the ROI. When analyzed as ratios, compensation
against systematic errors is achieved. For visualization purposes,
these analyses have been adjusted so they pass through the origin.
Immunohistochemical analyses
Tumors were resected, fixed in 2% buffered formaldehyde,
dehydrated, embedded in paraffin and sectioned. Sections were
deparaffinized with xylene, rehydrated, microwaved and then
incubated overnight with monoclonal primary antibodies diluted
in 1% (wt/vol) bovine serum albumin and visualized using the
standard avidin–biotin–peroxidase complex technique (Vector
Laboratories, Burlingame, CA, USA). Counterstaining was
performed with Mayer’s haematoxylin. Antibody against active
caspase-3 was from Pharmingen and used at 1:1000. Scoring of
positive cells was performed for three randomly chosen fields of
view for each tumor by an independent observer unaware of
treatment, who scored the staining as 0–100% positivity. The
mean value of this score from the three fields of view was used as
the immunohistochemistry score for each tumor.
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Analysis of circulating K18 fragments
Soluble ccK18 and K18 fragments in mouse plasma were
determined by the M30 ApoptosenseH and M65H ELISA assays
[13,17] (Peviva AB, Bromma, Sweden) (note: even though plasma
was used in the present study the analyte is generally referred to as
a ‘‘serum biomarker’’ in the literature and we have chosen to do so
here). M30 ApoptosenseH is a sandwich immunoassay based on
two monoclonal antibodies: M30 and M5. M30 recognizes a K18
neo-epitope generated by caspase cleavage during apoptosis, but
does not recognize uncleaved K18. M5 recognizes an epitope in
the 284–396 region of K18. The M65 ELISAH measures total
soluble K18 fragments using the M5 and M6 monoclonal
antibodies and measures total epithelial cell death [17]. Neither
M30 nor M5 recognize mouse K18; the M30 ApoptosenseH and
M65H ELISA assays are therefore specific for tumor apoptosis/cell
death when plasma is analyzed from mice carrying human tumor
xenografts [17]. The ELISA’s were used according to the
instructions of the manufacturer (except that 12.5 ml plasma
sample was used). HBR-Plus blocking reagent was used to reduce
background observed in mouse plasma (lot#5130, conc. 10.6 mg/
ml; 3KC579; Scantibodies laboratory Inc, Santee CA, USA),
0.4 ml of per sample
Statistical methods
Data from biomarker analyses (IHC scores, M30 Apoptosense
and binding potentials in PET imaging) were presented as median
values. Analysis of correlation was performed using the Spearman
nonparametric test (Prism software). To test for statistically
significant differences between any two groups, the nonparametric
Mann-Whitney U method not assuming Gaussian distribution was
used (Prism software). All tests were two-tailed.
Results
Induction of cell death by doxorubicin in FaDu tumor
xenograft tissue
Human FaDu head-neck carcinoma shows a modest response to
DNA damaging agents, resulting in tumor growth retardation but
not in eradication [20]. Thus these cells were used here in mouse
xenografts to model clinical reality and to challenge the levels of
sensitivity for the cell death detection methods.
First the extent of cell death provoked by a single dose of
doxorubicin in the FaDu xenograft tumors was determined by
staining sections of excised tumors from non-treated and treated
animals with an antibody recognizing active caspase-3. Basal levels
of apoptosis were observed in tumors from non-treated mice and
these levels were increased in tumors from animals excised
72 hours after doxorubicin treatment as evaluated by this
immunohistochemical approach (Fig. 1A). The patterns of
apoptosis were, however, heterogeneous in the tissue sections
and were in some sections similar to that in the untreated control.
The statistical analyses of the immunohistochemictry scoring
results confirmed the induction of a modest increase in apoptosis
using this treatment protocol (Fig. 1B).
PET Imaging using [11C]-AnxA5-ST and a size-matched
control ligand
Evaluation of therapeutic responses by imaging has the
advantages that it is non-invasive, provides positional information
and samples over the entire tumor (as opposed to sectioning for
immunohistochemistry). For imaging tumor cell death we here
used [11C]-AnxA5-ST. To assess passive tissue uptake of protein
tracer into tumor tissue due to EPR effects [6,7], we used the
control ligand [11C]-mTrx-GFP-ST that is presumed to lack
biological effects in a mammalian host (for details see Materials and
Methods and Material S1). First we verified that fluorescently
labeled AnxA5-ST, but not mTrx-GFP-ST, bound to doxorubi-
cin-treated FaDu cells in culture (Fig. S1). Thereafter the two
ligands were site-specifically 11C-labeled at the Sec residue in their
Sel-tag motifs and used for dynamic PET imaging with the FaDu
cell xenograft-bearing mice.
Graphical analyses for the quantification of uptake of radioac-
tivity in tissues performed as described [26,27,28] revealed that the
uptake from [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST were
similar in untreated human FaDu cell xenograft tumors (Figs 2A,
2B), suggesting that these basal levels were largely due to passive
uptake. At 72 h after a single dose of doxorubicin (5 mg/kg s.c.),
[11C]-AnxA5-ST uptake in tumors was elevated compared to the
untreated tumors. The treatment-induced increases were of a
magnitude consistent with the levels of increased caspase-positivity
in tissue sections (Fig. 1). Changes in the distribution volume
ratio, as illustrated in Logan plots [28], provided robust read-outs
for the increases of [11C]-AnxA5-ST uptake (Fig. 2C). In contrast,
doxorubicin treatment did not increase the distribution volume
ratio for the control ligand [11C]-mTrx-GFP-ST (Fig. 2C).
Imaging showed a statistically significant increase in the tumor
binding potential of [11C]-AnxA5-ST after doxorubicin, which
was even larger if compared to [11C]-mTrx-GFP-ST (Fig. 2D).
Distribution volume ratios assessed at 48 h after a lower dose of
doxorubicin (2.5 mg/kg s.c.) were in between the baseline levels
and those after the higher dose at 72 h (Fig. S2).
PET imaging with either [11C]-AnxA5-ST or [11C]-mTrx-
GFP-ST compared to [18F]-FDG
The short half-life of 11C allowed scans with [18F]-FDG
(Fig. 3C, 3D) to be performed within a few hours after imaging
with either [11C]-AnxA5-ST or [11C]-mTrx-GFP-ST. [18F]-FDG
was more rapidly taken up in the tumor in baseline and treated
animals compared to the protein ligands (cf. Fig. 2A, 2B and
Fig. 3A, 3B, 3C, 3D, 3F), consistent with a more rapid
distribution of small water-soluble carbohydrates from blood into
tissues. However, in contrast to the drug-induced increases in
[11C]-AnxA5-ST uptake, the tumor uptake of [18F]-FDG was
unchanged at 72 hrs after the doxorubicin treatment, as compared
to untreated mice (Fig. 3E) or compared to [11C]-mTrx-GFP-ST
(Fig. 3F).
Increased levels of circulating cell death biomarkers
We found that the plasma levels of caspase-cleaved K18 (ccK18)
were significantly increased when sampled 72 hours after doxo-
rubicin treatment as compared to untreated tumor-bearing mice
(p = 0.0007, Fig. 4A). The increases were larger than expected
from in situ detection of apoptosis by staining for active caspase-3
and larger than those observed during PET imaging with [11C]-
AnxA5-ST. We furthermore determined the levels of human
circulating total K18 using the M65 ELISA, a biomarker for total
cell death [13], which also showed a pronounced increase in levels
comparing treated animals with controls (p = 0.016, Fig. 4A).
Assessment of active caspase-3 by immunohistochemistry showed
considerable variability between individual sections from the same
tumor (Fig. S3). This is in contrast to imaging and serum
biomarker analyses, which will reflect apoptosis/cell death of the
entire tumor mass. Indeed, when examining correlations between
the tumor binding potentials of the [11C]-AnxA5-ST tracer and
levels of circulating ccK18 fragments in tumor-bearing animals,
these were found to be significant (p = 0.023 by Spearman rank
correlation, Fig. 4B), as they also were between [11C]-AnxA5-ST
Imaging and Serum Biomarkers in Therapy Evaluation
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binding potentials and plasma K18 (p = 0.007, Fig. 4C). This
suggested that both the [11C]-AnxA5-ST tumor binding potentials
and ccK18 levels in plasma could be used as reliable biomarkers
for therapy-induced cell death. In contrast, there was no
correlation between [11C]-mTrx-GFP-ST binding potentials and
either ccK18 or K18 (p = 0.50 and p = 0.87, respectively).
Although both the serum markers and PET imaging of tumor
uptake with [11C]-AnxA5-ST displayed statistically significant
Figure 1. Assessment of tumor cell death using immunohistochemistry. A) Illustrative immunohistochemical analyses of active caspase-3
(staining dark brown) in tumor tissue before (left) or 72 h after treatment with a single dose doxorubicin (right), showing increased tumor apoptosis
in situ. B) Summary of immunohistochemistry (IHC) scores in FaDu xenografts analyzed postmortem with (triangles, n=6) or without (squares, n= 7)
prior doxorubicin treatment for 72 h. Vertical line shows median and the single asterisk indicates the statistical significance between the two groups
(p= 0.0381). Each tumor score represents the mean score from analyses of three separate fields of view per tumor evaluated by a person unaware of
treatment and setting an arbitrary score between 0 (no apparent staining) to 100 (all cells staining positive).
doi:10.1371/journal.pone.0042151.g001
Figure 2. Increased tumor uptake upon doxorubicin treatment using [11C]-AnxA5-ST but not [11C]-mTrx-GFP-ST. A) MIP and transaxial
images of radioactivity (summed over 10–55 min) after tail vein injection of [11C]-AnxA5-ST (left) or [11C]-mTrx-GFP-ST (right) in a mouse bearing a
FaDu xenograft without doxorubicin treatment. B) Time activity curves for tumor uptake of [11C]-AnxA5-ST (solid squares or solid line) and [11C]-mTrx-
GFP (empty squares or dashed line) in untreated mice (lines) or 72 h after a single-dose treatment with doxorubicin (squares). Note the similar uptake
of [11C]-AnxA5-ST and [11C]-mTrx-GFP-ST in untreated mice, due to the non-specific EPR effect, while upon doxorubicin treatment an increase in [11C]-
AnxA5-ST uptake was seen in contrast to a non-statistically significant tendency to decrease of [11C]-mTrx-GFP-ST. C) Logan plot analyses of
distribution volumes of [11C]-AnxA5-ST or [11C]-mTrx-GFP-ST in FaDu xenograft tumors in untreated and doxorubicin treated mice (symbols as in
panel B). D) Diagram summarizing tumor binding potential in PET imaging using either [11C]-AnxA5-ST (solid symbols) or the size-matched control
protein [11C]-mTrx-GFP-ST (open symbols) with the mice carrying FaDu xenograft tumors, either with (squares, n=9 for [11C]-AnxA5-ST and n= 6 for
[11C]-mTrx-GFP-ST) or without (triangles, n= 12 for [11C]-AnxA5-ST and n= 8 for [11C]-mTrx-GFP-ST), with asterisks indicating statistical significance
between pair of groups. The p values were as follows: [11C]-AnxA5-ST in untreated tumors vs. the same ligand in doxorubicin treated: p= 0.0173; [11C]-
AnxA5-ST in doxorubicin treated tumors vs. [11C]-mTrx-GFP-ST in untreated tumors: p= 0.0152; [11C]-AnxA5-ST in doxorubicin treated tumors vs. [11C]-
mTrx-GFP-ST in doxorubicin treated tumors: p= 0.0048; remaining pair-wise comparisons showed a lack of statistically significant differences, as
indicated for [11C]-mTrx-GFP-ST with or without treatment (n.s. = no significance, p.0.1).
doi:10.1371/journal.pone.0042151.g002
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increases with treatment, the serum markers gave higher
magnitude in their increases and would thereby likely show better
sensitivity in cell death detection (cf. Fig. 2C and Fig. 4A). The
fold changes in median values after doxorubicin treatment were
about 1.5-fold higher for the binding potentials of [11C]-AnxA5-
ST whereas they were about 5-fold higher for the ccK18 marker
(see Fig. S4 for a summary of the fold changes). However, in spite
of its higher sensitivity the ccK18 marker can, naturally, not
localize the site of its generation. We therefore conclude that the
combination of PET imaging with [11C]-AnxA5-ST, to reveal the
localization of cell death, with determination of the serum ccK18
(M30) biomarker, as a measure of accumulated cell death, should
be a promising method for assessment of therapeutic efficacy.
Discussion
Assessment of whether drug treatment induces cell death in
solid tumors when using biopsy material is complicated by the fact
that the levels observed in tissue sections are variable, both at base-
line and following therapy. This variability is likely to reflect tumor
heterogeneity and the presence of different clones in the tumor,
showing different rates of spontaneous cell death and different
sensitivities to the drug used. Assessment of treatment responses
therefore requires both paired tumor samples (before and after
Figure 3. Response to doxorubicin at 72 h is revealed with [11C]-AnxA5-ST but not [18F]-FDG or [11C]-mTrx-GFP-ST. Representative
MIP and transaxial images of radioactivity (summed over 35–55 min) after tail vein injection in mice with FaDu xenografts of A) [11C]-AnxA5-ST or B)
[11C]-mTrx-GFP-ST, 72 h after treatment with a single dose of doxorubicin (5 mg/kg). Also shown are representative images of [18F]-FDG, at C)
baseline or, alternatively, D) after treatment with doxorubicin and 90 min after the image with [11C]-AnxA5-ST in A). E) Time activity curves of single
tumors showing uptake of [11C]-AnxA5-ST (solid triangles and squares) or [18F]-FDG (lines) before (solid triangle and dashed line) or after doxorubicin
treatment (solid squares and solid line). F) Corresponding experiments showing a comparison between of [11C]-mTrx-GFP-ST (empty triangles and
squares) and [18F]-FDG (lines) tumor uptake in the same mouse before (empty triangles and dashed line) or after doxorubicin treatment (empty
squares and solid line).
doi:10.1371/journal.pone.0042151.g003
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therapy) and several biopsy cores. Pharmacokinetics of a
chemotherapeutic drug as well as the inherent kinetics of cell
death processes clearly also affect the results at any given time
point. Imaging techniques are hence powerful alternatives as they
may integrate the overall response of a tumor and can therefore be
less affected by tumor heterogeneity at a microscopic level, while
still providing positional information. Imaging methods also have
the capacity to detect off-target toxicity to non-tumor tissue. Other
factors, however, complicate tumor cell death imaging, such as the
phenomenon of non-specific uptake of tracer in tumor tissue due
to EPR effects [7] and possible effects of anti-cancer drugs on the
vasculature thereby affecting tracer deposition. Using [11C]-mTrx-
GFP-ST to examine EPR effects we found a tendency for decrease
in uptake upon doxorubicin treatment at 72 hours, even though it
was not statistically significant. Doxorubicin has indeed been
reported to affect endothelial cell function [29] and the actual
imaging read-out for assessment of the AnxA5-specific uptake
should therefore be the difference between [11C]-AnxA5-ST and
Figure 4. Correlations between increases in serum marker levels and tumor [11C]-AnxA5-ST binding potentials upon doxorubicin
treatment. A) Levels of ccK18 (M30 ApoptosenseH) and K18 (M65H) determined in plasma of mice carrying FaDu xenograft tumors, either with (red
symbols) or without (green symbols) prior doxorubicin treatment for 72 h. Statistical significance as given in the panels was determined by the Mann-
Whitney U test. B,C) Correlations between tumor binding potential in PET imaging using the [11C]-AnxA5-ST tracer and B) ccK18 and C) K18 plasma
levels for each mouse. Shown to the left in each panel are values of individual mice with the p-values of statistical analysis of correlation as performed
using the Spearman rank test given in the graphs. The plots to the right show the aggregated means 6 S.D. Red symbols: doxorubicin-treated mice;
green symbols: untreated mice.
doi:10.1371/journal.pone.0042151.g004
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[11C]-mTrx-GFP-ST uptakes after treatment, rather than [11C]-
AnxA5-ST alone compared to baseline. Whether changes in
passive tracer uptake have influenced abilities of other studies with
AnxA5 ligands to reveal therapy-induced cell death is unclear, but
can not be excluded. To our knowledge, this is the first PET study
comparing a size-matched ligand with AnxA5 to discriminate
different chemotherapy effects in a tumor xenograft model using
PET imaging.
In the FaDu tumor model used here, the amplitude of increased
uptake of [11C]-AnxA5-ST following doxorubicin treatment was
similar to that which could be expected from the extent of increase
in the number of apoptotic cells in tissue at that time point.
Interestingly, the increases in the levels of the serum K18
biomarkers – and in particular ccK18 (the M30 ELISA analyte)
- were clearly larger than the increases in tumor binding potential
for [11C]-AnxA5-ST. A possible explanation for the strong
increases in circulating K18 molecules should be that they are
accumulated in the blood after instigation of apoptosis [12]. The
higher signals increase sensitivity in detection for the entire time
interval since start of treatment, but serum biomarkers have the
disadvantage of not providing regional information about the
source of the cell death signal. We therefore believe that the
combination of sensitive serum cell death biomarkers with in vivo
tissue cell death imaging using PET should be attractive for
accurately determining treatment responses as well as toxic side
effects to off-target tissues.
In conclusion, our results illustrate the feasibility of studying cell
death through multimodality and multi-tracer imaging strategies
utilizing 11C-labeled Sel-tagged proteins. Comparing the uptake of
AnxA5 with a size-matched control and using dynamic imaging
protocols were fundamentally important for revealing the therapy-
induced responses. We propose that these imaging biomarkers can
provide information about therapeutic responses, as here to
doxorubicin, that is discrete from the metabolic read-outs obtained
with the more widely used imaging biomarker [18F]-FDG.
Furthermore, complementing the imaging with measurements of
the circulating serum biomarkers of cell death, ccK18/K18,
increases the total sensitivity of the detection. Since both methods
are comparatively rapid and used with live mice, this approach
provides a promising platform for determinations of both kinetics
and tissue specificities in cell death detection as well as potential
multiple effects of the therapeutics during drug development using
xenograft tumor models in mice.
Supporting Information
Material S1 Detailed description of the new AnxA5-ST and
mTrx-GFP-ST PET ligands, including amino acid sequences and
description of functional domains.
(DOCX)
Figure S1 AnxA5-ST maintains specific binding to
apoptotic cells when labeled with fluorescence at its
Sec residue whereas mTrx-GFP-ST does not bind
apoptotic cells. Fluorescence microscopy (top) or phase contrast
(bottom) pictures of FaDu cells exposed to 0.2 mM doxorubicin for
48 hours and incubated with 0.5 mg/ml of either [AF]-AnxA5-ST
(left) or [AF]-mTrx-GFP (right) for 20 min at 37uC. Fluorescence
labeling at the Sel-tag was performed as described in the Materials
and Methods section.
(JPEG)
Figure S2 Uptake of [11C]-AnxA5-ST in tumors with two
separate doxorubicin treatment regimes. Logan plots are
shown for [11C]-AnxA5-ST tumor uptake in untreated controls or
after 48-hour doxorubicin treatment (2.5 mg/kg) or 72-hour
treatment (5 mg/kg), compared to [11C]-mTrx-GFP-ST in either
untreated tumors or after 72-hour doxorubicin treatment (5 mg/
kg), as indicated. The binding potential of [11C]-AnxA5-ST was,
as expected, intermediate using the intermediate dose. This dose
was not analyzed using [11C]-mTrx-GFP-ST. For further analyses
see Supplementary Fig. S3 and the main text of the study.
(PDF)
Figure S3 Illustration of variability between tumors and
tumor sections receiving the same treatment and
comparisons between [11C]-AnxA5-ST imaging, active
caspase-3 staining and M30/M65 scores for the same
tumors. Two illustrative examples are shown each for tumors of
untreated mice (top), 48-hour doxorubicin treatment (2.5 mg/kg)
or 72-hour treatment (5 mg/kg), with PET image of the tumor
using [11C]-AnxA5-ST shown to the left, three sections of each
tumor to the right (with IHC scores) and a summary of the data
including M30/M65 scores to the left. See text for further details.
(JPEG)
Figure S4 Fold changes upon doxorubicin treatment in
the signal of biomarkers studied herein. This bar graph
illustrates the fold changes in biomarker signals detected upon 72-
hour after a single-dose doxorubicin treatment (5 mg/kg). The
bars illustrate the ratio of median values for treated animals over
controls, with binding potentials determined through Logan plots
for [11C]-AnxA5-ST or [11C]-mTrx-GFP-ST as well as the M30
or M65 serum markers. For further details please see the main text
of the study.
(JPEG)
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